Galapagos extends target discovery alliance with Cystic Fibrosis Foundation Therapeutics
Advertisement
Galapagos NV announced the extension of the target discovery alliance between its service division BioFocus DPI and cystic fibrosis Foundation Therapeutics, Inc. (CFFT), the drug discovery and development affiliate of the Cystic Fibrosis Foundation. This 15-month extension exceeds EUR800,000 in research fees and builds further on the alliance initiated in April 2005. BioFocus DPI is applying its SilenceSelect adenoviral library and expertise in assay design to discover novel drug targets for the development of new cystic fibrosis therapies.
"The project to discover novel targets for cystic fibrosis is proceeding very well, and we are therefore pleased and proud that Cystic Fibrosis Foundation Therapeutics has extended the alliance. This will enable BioFocus DPI to deliver validated targets as the basis for the development of new medicines," said Onno van de Stolpe, Chief Executive Officer of Galapagos. "It is particularly gratifying that our target discovery engine is being applied to the unmet medical needs addressed by patient foundations such as the Cystic Fibrosis Foundation."
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Biotools, B & M Labs, S.A. - Madrid, Spain
Structure of key complex in the immune system - New study reveals the structure of complement component C1 – a target for complement-mediated diseases including strokes and heart attacks
Computer tool analyzes in detail genetic alterations in the genome of cancer cells - Developed by CSIC, CiberAMP allows establishing direct correlations between changes in the number of gene copies in tumor cells and their expression levels
Proteros and CHDI Foundation, Inc. establish discovery services collaboration to address Huntington’s disease
Horizon Discovery Group plc, Centre for Process Innovation and University of Manchester Awarded £1.67M - Consortium to receive funding to develop enhanced biomanufacturing platforms based on the Company’s CHO cell line and gene editing platform